AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12371383 — intervention group
Group type: EXPERIMENTAL
Intervention: NITRO‐15
Number of subjects: 15
Study 12371383 — intervention group
Group type: EXPERIMENTAL
Intervention: PENTA‐100
Number of subjects: 15
Study 12371383 — intervention group
Group type: COMPARATOR
Intervention: P (Placebo)
Number of subjects: 15
Study 8879603 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker + diuretics
Number of subjects: 6628
Study 8879603 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 6628
Study 8879603 — intervention group
Group type: COMPARATOR
Intervention: calcium antagonists
Number of subjects: 6628
Study 8879603 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 6628
Study 2271853 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics taken by 325 men for a mean of 11.9 years
Number of subjects: 1017
Study 2271853 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antihypertensive drugs taken by 53 men
Number of subjects: 1017
Study 2271853 — intervention group
Group type: COMPARATOR
Intervention: Control group (639 men without hypertension)
Number of subjects: 1017
Study 6968205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory angular acceleration (aR) at 1 Hz
Number of subjects: 14
Study 6968205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory angular acceleration (aR) at 5 Hz
Number of subjects: 14
Study 6968205 — intervention group
Group type: COMPARATOR
Intervention: No vibratory angular acceleration (aR)
Number of subjects: 14
Study 6968205 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant aR presented for 0.5 and 1.0 s
Number of subjects: 14
Study 6968205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory aR conditions (1 Hz and 5 Hz)
Number of subjects: 14
Study 31455938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-and-mask ventilation with monitor displayed
Number of subjects: 82
Study 31455938 — intervention group
Group type: COMPARATOR
Intervention: Bag-and-mask ventilation without monitor displayed
Number of subjects: 82
Study 28369211 — intervention group
Group type: COMPARATOR
Intervention: GSK3532795 5-120 mg once daily for 10 days (Part A)
Number of subjects: 0
Study 28369211 — intervention group
Group type: COMPARATOR
Intervention: GSK3532795 40 mg or 80 mg once daily with atazanavir (ATV) ± ritonavir (RTV) for 28 days (Part B)
Number of subjects: 0
Study 28369211 — intervention group
Group type: COMPARATOR
Intervention: GSK3532795 40 mg or 120 mg once daily for 10 days (Part C)
Number of subjects: 0
Study 26342888 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-20mg escitalopram
Number of subjects: 28
Study 26342888 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy elderly (control group)
Number of subjects: 28
Study 23722951 — intervention group
Group type: EXPERIMENTAL
Intervention: Real electroacupuncture (EA) twice weekly for 6 weeks
Number of subjects: 32
Study 23722951 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (EA) twice weekly for 6 weeks
Number of subjects: 32
Study 21217439 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted quantitative motion analysis (QMA) software
Number of subjects: 6
Study 21217439 — intervention group
Group type: COMPARATOR
Intervention: Digitized manual technique
Number of subjects: 6
Study 19201630 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal osteotomy
Number of subjects: 32
Study 19201630 — intervention group
Group type: COMPARATOR
Intervention: Lateral osteotomy
Number of subjects: 32
Study 17519278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with methotrexate (MTX)
Number of subjects: 299
Study 17519278 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with methotrexate (MTX)
Number of subjects: 299
Study 15291291 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat-related chronic PTSD (N=43)
Number of subjects: 123
Study 15291291 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat-related chronic PTSD comorbid with alcohol dependence (N=41)
Number of subjects: 123
Study 15291291 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=39)
Number of subjects: 123
Study 15291291 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group (N=43)
Number of subjects: 123
Study 15291291 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD comorbid with alcohol dependence (N=41)
Number of subjects: 123
Study 11159760 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g meat/day
Number of subjects: 8
Study 11159760 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 g meat/day
Number of subjects: 8
Study 11159760 — intervention group
Group type: EXPERIMENTAL
Intervention: 420 g meat/day
Number of subjects: 8
Study 11159760 — intervention group
Group type: COMPARATOR
Intervention: 0 g meat/day
Number of subjects: 8
Study 11159760 — intervention group
Group type: EXPERIMENTAL
Intervention: 420 g meat/day for 40 days
Number of subjects: 8
Study 11159760 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher meat diets
Number of subjects: 8
Study 11159760 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer transit times in the gut
Number of subjects: 8
Study 11159760 — intervention group
Group type: EXPERIMENTAL
Intervention: Low faecal weight
Number of subjects: 8
Study 10093071 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm‐ECD
Number of subjects: 11
Study 10093071 — intervention group
Group type: COMPARATOR
Intervention: 99Tcm‐HMPAO
Number of subjects: 11
Study 7697230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination dry powder inhaler (Turbuhaler) containing terbutaline (250 micrograms) with budesonide (200 micrograms)
Number of subjects: 74
Study 7697230 — intervention group
Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 74
Study 7697230 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 74
Study 2776952 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 39
Study 2776952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 901135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward environment perceived as lower in allowance of expression of anger and aggression, higher in order and organization (staff's perception)
Number of subjects: 14
Study 901135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward environment perceived as homogeneous in outcome and assessments of order and organization and freedom to express anger and aggression
Number of subjects: 14
Study 31861993 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 26
Study 27780334 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 0
Study 27780334 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 0
Study 27780334 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 0
Study 27780334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25599538 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond lenticule extraction (FLEx)
Number of subjects: 30
Study 25599538 — intervention group
Group type: COMPARATOR
Intervention: Small incision lenticule extraction (SMILE)
Number of subjects: 30
Study 23820094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 303
Study 23820094 — intervention group
Group type: COMPARATOR
Intervention: Person-Centred Therapy (PCT)
Number of subjects: 303
Study 23820094 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated CBT
Number of subjects: 303
Study 23820094 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-focused CBT
Number of subjects: 303
Study 23820094 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered integrated CBT
Number of subjects: 303
Study 23820094 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered integrated CBT
Number of subjects: 303
Study 23820094 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (1 session)
Number of subjects: 303
Study 21364502 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 50
Study 21364502 — intervention group
Group type: COMPARATOR
Intervention: uLMA
Number of subjects: 50
Study 19334007 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention including passive movements/mobilizations, active movement/mobilizations, home exercise programme, education and advice, and ultrasound.
Number of subjects: 98
Study 19334007 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 98
Study 17093161 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation
Number of subjects: 70
Study 17093161 — intervention group
Group type: COMPARATOR
Intervention: Iron-folate supplementation (control)
Number of subjects: 70
Study 15017802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tractors operated by children
Number of subjects: 1113
Study 15017802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tractors of at least 20 horsepower operated by children
Number of subjects: 1113
Study 15017802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tractors equipped with ROPS
Number of subjects: 1113
Study 11696921 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + irrigation with collagen gel containing 1% chlorhexidine (group 3)
Number of subjects: 6
Study 11696921 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + irrigation with collagen gel (group 2)
Number of subjects: 6
Study 11696921 — intervention group
Group type: COMPARATOR
Intervention: SRP only (group 1)
Number of subjects: 6
Study 9440363 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous trial involved a nonword
Number of subjects: 0
Study 9440363 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous trial involved a nonword or pseudohomophone
Number of subjects: 0
Study 9440363 — intervention group
Group type: COMPARATOR
Intervention: Previous trial involved a word
Number of subjects: 0
Study 8535199 — intervention group
Group type: EXPERIMENTAL
Intervention: RCM protocol: response-oriented cyclic multidrug protocol
Number of subjects: 43
Study 2691317 — intervention group
Group type: EXPERIMENTAL
Intervention: Shosaiko-to (SST) 5.4 g daily for 12 weeks
Number of subjects: 222
Study 2691317 — intervention group
Group type: COMPARATOR
Intervention: Placebo 0.5 g of SST for 12 weeks
Number of subjects: 222
Study 2691317 — intervention group
Group type: EXPERIMENTAL
Intervention: Shosaiko-to (SST) after crossover from placebo
Number of subjects: 222
Study 30052924 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise program with motivational interviewing
Number of subjects: 69
Study 30052924 — intervention group
Group type: COMPARATOR
Intervention: Usual PA recommendations
Number of subjects: 69
Study 28845695 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week Tai Chi intervention
Number of subjects: 39
Study 28845695 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-week Tai Chi intervention
Number of subjects: 39
Study 28845695 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 26955704 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion (0.05 mg · kg(‐1) · min(‐1) for 24 hours)
Number of subjects: 48
Study 26955704 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 48
Study 22674544 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous stimulation (CS, n = 10)
Number of subjects: 40
Study 22674544 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous nonperiodic stimulation (DnPS, n = 10)
Number of subjects: 40
Study 22674544 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous periodic stimulation (DPS, n = 10)
Number of subjects: 40
Study 22674544 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent stimulation (AbS, n = 10)
Number of subjects: 40
Study 23198465 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-sandwich technique using Ketac Molar set with ultrasound (US)
Number of subjects: 100
Study 23198465 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z250 (control group)
Number of subjects: 100
Study 19614947 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 267
Study 19614947 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 267
Study 16791109 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 0.2 microg/kg/min
Number of subjects: 35
Study 15199073 — intervention group
Group type: EXPERIMENTAL
Intervention: telavancin 7.5 mg/kg
Number of subjects: 160
Study 15199073 — intervention group
Group type: EXPERIMENTAL
Intervention: telavancin 15 mg/kg
Number of subjects: 160
Study 15199073 — intervention group
Group type: COMPARATOR
Intervention: moxifloxacin 400 mg (positive control)
Number of subjects: 160
Study 15199073 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study 11255588 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple dissemination method
Number of subjects: 223
Study 11255588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dissemination method
Number of subjects: 223
Study 11255588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dissemination methods
Number of subjects: 223
Study 11255588 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 223
Study 11255588 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 223
Study 9291289 — intervention group
Group type: EXPERIMENTAL
Intervention: native phospholipase A2 (nPLA)
Number of subjects: 85
Study 9291289 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant phospholipase A2 (rPLA)
Number of subjects: 85
Study 9291289 — intervention group
Group type: EXPERIMENTAL
Intervention: specific serum IgE to BV
Number of subjects: 85
Study 9291289 — intervention group
Group type: EXPERIMENTAL
Intervention: specific serum IgE to nPLA
Number of subjects: 85
Study 9291289 — intervention group
Group type: EXPERIMENTAL
Intervention: specific serum IgE to rPLA
Number of subjects: 85
Study 8286162 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents receiving a copy of the letter from the paediatrician to the GP
Number of subjects: 89
Study 8286162 — intervention group
Group type: COMPARATOR
Intervention: Parents not receiving a copy of the letter from the paediatrician to the GP (comparison group)
Number of subjects: 89
Study 2886533 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef at 6 g day‐1
Number of subjects: 102
Study 2886533 — intervention group
Group type: COMPARATOR
Intervention: Latamoxef at 3 g day‐1
Number of subjects: 102
Study 31841687 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM-T
Number of subjects: 56
Study 31841687 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM-T + PDT
Number of subjects: 56
Study 30140929 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Microscopy (TM)
Number of subjects: 87
Study 30140929 — intervention group
Group type: COMPARATOR
Intervention: Whole-Slide Imaging (WSI)
Number of subjects: 87
Study 28634649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day)
Number of subjects: 0
Study 25439435 — intervention group
Group type: EXPERIMENTAL
Intervention: AKB‐9778 15 mg or more twice daily
Number of subjects: 24
Study 25439435 — intervention group
Group type: EXPERIMENTAL
Intervention: AKB‐9778 22.5 mg or more twice daily
Number of subjects: 24
Study 23972322 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants alone
Number of subjects: 995
Study 23972322 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and antioxidants
Number of subjects: 995
Study 23972322 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-containing regimens
Number of subjects: 995
Study 23972322 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 995
Study 23972322 — intervention group
Group type: EXPERIMENTAL
Intervention: Any category of AREDS treatment
Number of subjects: 995
Study 23972322 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-only supplementation
Number of subjects: 995
Study 23972322 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-only supplementation
Number of subjects: 995
Study 23972322 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 995
Study 21225699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg on days 1 and 15)
Number of subjects: 208
Study 21225699 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anti‐CCP antibodies or RF
Number of subjects: 208
Study 21225699 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IgG concentration above normal
Number of subjects: 208
Study 21225699 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of RF or anti‐CCP antibodies and elevated IgG
Number of subjects: 208
Study 19006481 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 0
Study 16543538 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill training (4 weeks, supervised)
Number of subjects: 16
Study 16543538 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (no training during weeks 3-6)
Number of subjects: 16
Study 13129638 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.526 U I-125 seeds
Number of subjects: 20
Study 13129638 — intervention group
Group type: COMPARATOR
Intervention: 0.414 U I-125 seeds
Number of subjects: 20
Study 10753248 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacer group (albuterol 600 microg by MDI with spacer)
Number of subjects: 60
Study 10753248 — intervention group
Group type: COMPARATOR
Intervention: Nebulizer group (2.5 mg albuterol by nebulizer)
Number of subjects: 60
Study 10753248 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacer group
Number of subjects: 60
Study 10753248 — intervention group
Group type: COMPARATOR
Intervention: Nebulizer group
Number of subjects: 60
Study 8884922 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intake of CoQ10
Number of subjects: 31
Study 1362841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol 2% ointment applied once daily for 8 weeks
Number of subjects: 27
Study 1362841 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied once daily for 8 weeks
Number of subjects: 27
Study 1362841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol treatment
Number of subjects: 27
Study 6385701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine heparin
Number of subjects: 141
Study 6385701 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine heparin
Number of subjects: 141
Study 6385701 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 141
Study 30958051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) at 15°C for 15 min
Number of subjects: 11
Study 30958051 — intervention group
Group type: COMPARATOR
Intervention: Phase Change Material (PCM) at 15°C for 3 h
Number of subjects: 11
Study 29782641 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural oxycodone 0.1 mg·kg-1
Number of subjects: 30
Study 29782641 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxycodone 0.1 mg·kg-1
Number of subjects: 30
Study 26838142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mango-flavored candy
Number of subjects: 30
Study 26838142 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk chocolate
Number of subjects: 30
Study 26838142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and nuts chocolate
Number of subjects: 30
Study 26838142 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Number of subjects: 30
Study 26838142 — intervention group
Group type: EXPERIMENTAL
Intervention: All chocolates assessed
Number of subjects: 30
Study 25106506 — intervention group
Group type: COMPARATOR
Intervention: Letter reminder (CONTROL)
Number of subjects: 600
Study 25106506 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder (TEL)
Number of subjects: 600
Study 25106506 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder plus telephone support (TEL-SUPP)
Number of subjects: 600
Study 25106506 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder plus support plus anticipated regret (TEL-SUPP-AR)
Number of subjects: 600
Study 23137512 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP guided care aiming to reduce NT-proBNP values ≤1000 pg/mL
Number of subjects: 151
Study 23137512 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) HF management
Number of subjects: 151
Study 23137512 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP guided care
Number of subjects: 151
Study 20381658 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin (HbA(1c)) assessment during hospitalization or documented in the chart from the preceding 3 months
Number of subjects: 1168
Study 20381658 — intervention group
Group type: EXPERIMENTAL
Intervention: Good control of HbA(1c) (<7%)
Number of subjects: 1168
Study 20381658 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal control of HbA(1c) (7% to 9%)
Number of subjects: 1168
Study 20381658 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor control of HbA(1c) (>9%)
Number of subjects: 1168
Study 20381658 — intervention group
Group type: EXPERIMENTAL
Intervention: DM treatment intensification for suboptimal control (HbA(1c) 7% to 9%)
Number of subjects: 1168
Study 20381658 — intervention group
Group type: EXPERIMENTAL
Intervention: DM treatment intensification for poor control (HbA(1c) >9%)
Number of subjects: 1168
Study 20381658 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions on DM disease management before discharge
Number of subjects: 1168
Study 18431346 — intervention group
Group type: EXPERIMENTAL
Intervention: MC-1 250 mg/day
Number of subjects: 901
Study 18431346 — intervention group
Group type: EXPERIMENTAL
Intervention: MC-1 750 mg/day
Number of subjects: 901
Study 18431346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 901
Study 15896928 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 127
Study 15896928 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 127
Study 15896928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study 11874394 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 5161
Number of subjects: 32
Study 11874394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32